Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.

[1]  H. Timmerman,et al.  1,5-Diphenyl-1,4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship , 1997 .

[2]  K. N. Rajasekharan,et al.  Antimutagenic and anticarcinogenic activity of natural and synthetic curcuminoids. , 1996, Mutation research.

[3]  David F. V. Lewis,et al.  Baseline Lipophilicity Relationships in Human Cytochromes P450 Associated with Drug Metabolism , 2003, Drug metabolism reviews.

[4]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[5]  H. Timmerman,et al.  Synthesis of some symmetrical curcumin derivatives and their antiinflammatory activity , 1997 .

[6]  D. Russell,et al.  Clinical importance of the cytochromes P450 , 2002, The Lancet.

[7]  J. Bridges,et al.  The role of substrate lipophilicity in determining type 1 microsomal P450 binding characteristics. , 1978, Biochemical pharmacology.

[8]  V. Keshamouni,et al.  Curcumin for malaria therapy. , 2005, Biochemical and biophysical research communications.

[9]  T. Shimada,et al.  Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons. , 2006, Chemical research in toxicology.

[10]  M. DeVito,et al.  Inhibition of human and rat CYP1A2 by TCDD and dioxin-like chemicals. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  G. Cole,et al.  NSAID and Antioxidant Prevention of Alzheimer's Disease: Lessons from In Vitro and Animal Models , 2004, Annals of the New York Academy of Sciences.

[12]  F. Pea,et al.  Pharmacokinetic Aspects of Treating Infections in the Intensive Care Unit , 2001, Clinical pharmacokinetics.

[13]  D. Lewis,et al.  QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS (QSARs) WITHIN CYTOCHROMES P450 2B (CYP2B) SUBFAMILY ENZYMES: THE IMPORTANCE OF LIPOPHILICITY FOR BINDING AND METABOLISM , 2006, Drug metabolism and drug interactions.

[14]  R. Then.  "Nonantibiotics"--their relevance in research and potential place in future antimicrobial chemotherapy. , 1992, Journal of chemotherapy.

[15]  Scott L Cockroft,et al.  The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[16]  P. Labute,et al.  Flexible alignment of small molecules. , 2001, Journal of medicinal chemistry.

[17]  D. Lewis,et al.  Quantitative structure-activity relationships (QSARs) for substrates of human cytochromes P450 CYP2 family enzymes. , 2004, Toxicology in vitro : an international journal published in association with BIBRA.

[18]  N. Vermeulen,et al.  Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. , 1996, Biochemical pharmacology.

[19]  K. Youssef,et al.  Synthesis of Curcumin Analogues as Potential Antioxidant, Cancer Chemopreventive Agents , 2004, Archiv der Pharmazie.

[20]  G. S. Walker,et al.  Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. , 2003, Chemical research in toxicology.

[21]  A. Gescher.  Polyphenolic Phytochemicals Versus Non-Steroidal Anti-Inflammatory Drugs: Which Are Better Cancer Chemopreventive Agents? , 2004, Journal of chemotherapy.

[22]  A. Olson,et al.  Active site binding modes of curcumin in HIV-1 protease and integrase. , 2005, Bioorganic & medicinal chemistry letters.

[23]  B. Ring,et al.  Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression , 2003, Journal of Pharmacology and Experimental Therapeutics.

[24]  Antti Poso,et al.  Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. , 2005, Journal of medicinal chemistry.

[25]  R. Mayer,et al.  Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. , 1985, Biochemical pharmacology.

[26]  S. Jee,et al.  Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. , 2001, Anticancer research.

[27]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[28]  R. Obach,et al.  Validated assays for human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[29]  Zhang Zy,et al.  Enzyme Kinetics for Clinically Relevant CYP Inhibition , 2005 .

[30]  D. Flockhart,et al.  In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. , 2000, British journal of clinical pharmacology.

[31]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. , 1964, The Journal of biological chemistry.

[32]  David A. Flockhart,et al.  Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A , 2001, Antimicrobial Agents and Chemotherapy.

[33]  J. Snyder,et al.  Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. , 2004, Bioorganic & medicinal chemistry.

[34]  M. Delaforge,et al.  CYTOCHROME P450-MEDIATED OXIDATION OF GLUCURONIDE DERIVATIVES: EXAMPLE OF ESTRADIOL-17β-GLUCURONIDE OXIDATION TO 2-HYDROXY-ESTRADIOL-17β-GLUCURONIDE BY CYP 2C8 , 2005, Drug Metabolism and Disposition.